Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Utah
Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system. Depression, or major depressive disorder, is highly prevalent in people with MS and often has a serious impact on quality of life. MDD can be difficult to treat with medications in MS. Transcranial magnetic stimulation (TMS) is a safe and approved treatment for treatment-resistant depression in the general population. However, little is known about the use of TMS for MDD in people with MS. This pilot study will evaluate the safety, feasibility, and preliminary efficacy of TMS for MDD in MS. Participants will receive outpatient neuronavigated-TMS for MDD. Various measures of MS and MDD symptoms will be monitored over the course of treatment. Clinical brain imaging will also be compared before and after TMS.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Established diagnosis of multiple sclerosis (any subtype) by 2017 McDonald criteria
Established diagnosis of major depressive disorder (MDD) by DSM-5 criteria
Eligible for transcranial magnetic stimulation (rTMS) for depression
You may not be if
MS relapse and/or steroid use within 3 months
Active suicidal ideation
History of seizure/epilepsy, brain tumor, or stroke